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Mesenchymal stem cells (MSCs) can become po-
tently immunosuppressive through unknown mech-
anisms. We found that the immunosuppressive
function of MSCs is elicited by IFNg and the con-
comitant presence of any of three other proinflam-
matory cytokines, TNFa, IL-1a, or IL-1b. These cyto-
kine combinations provoke the expression of high
levels of several chemokines and inducible nitric
oxide synthase (iNOS) by MSCs. Chemokines drive
T cell migration into proximity with MSCs, where
T cell responsiveness is suppressed by nitric oxide
(NO). This cytokine-induced immunosuppression
was absent in MSCs derived from iNOS/ or
IFNgR1/ mice. Blockade of chemokine receptors
also abolished the immunosuppression. Adminis-
tration of wild-type MSCs, but not IFNgR1/ or
iNOS/ MSCs, prevented graft-versus-host disease
in mice, an effect reversed by anti-IFNg or iNOS
inhibitors. Wild-type MSCs also inhibited delayed-
type hypersensitivity, while iNOS/ MSCs aggra-
vated it. Therefore, proinflammatory cytokines are
required to induce immunosuppression by MSCs
through the concerted action of chemokines and NO.
INTRODUCTION
Adult stem cells exist in many tissues, such as bone marrow,
muscle, fat, and brain. While most studies of adult stem cells
have focused on CD34+ hematopoietic stem cells, the distinct
lineage of CD34 fibroblast-like mesenchymal stem cells
(MSCs), especially those derived from bone marrow, have
attracted significant attention recently (Chen et al., 2006;
Keating, 2006; Pommey and Galipeau, 2006). Bone marrow-
derived MSCs have been shown to differentiate into several
different types of tissues, such as cartilage, bone, muscle, and
adipose tissue (Barry and Murphy, 2004; Le Blanc and Ringden,
2006).MSCs have been shown to be highly immunosuppressive, un-
like embryonic stem (ES) cells. In some studies, MSCs were
found to suppress T cell proliferation and cytokine production
(Dazzi et al., 2006; Keating, 2006; Rasmusson et al., 2005;
Sato et al., 2007; van Laar and Tyndall, 2006). MSCs have
been used to promote the engraftment of transplanted bone
marrow, CD34+ hematopoietic stem cells, and potentially ES
cells (Le Blanc and Ringden, 2006; Miszta-Lane et al., 2006).
Koc et al. found no evidence of alloreactive T cells and no inci-
dence of GvHD when as few as 2 3 106 allogeneic MSCs per kg
were infused along with allogeneic bone marrow into patients
with metachromatic leukodystrophy, or Hurler’s syndrome (Koc
et al., 2002). Others have attempted using MSCs to prevent or
treat autoimmune diseases, such as experimental autoimmune
encephalomyelitis (Zappia et al., 2005) and collagen-induced ar-
thritis (Djouad et al., 2005). We recently found that MSCs prevent
the rejection of allogeneic skin grafts (Xu et al., 2007a). MSC-
mediated immunosuppression has been variously demonstrated
to involve IL-10 (Batten et al., 2006), TGF-b (Groh et al., 2005),
nitric oxide (Sato et al., 2007), indoleamine 2,3-dioxygenase
(IDO) (Meisel et al., 2004), and prostaglandin (PG) E2 (Aggarwal
and Pittenger, 2005); the exact mechanism is uncertain. Accord-
ing to our recent findings, however, IL-10 and TGFb are not in-
volved (Xu et al., 2007a). Interestingly, the immunomodulatory
effect of MSCs is not always achieved; in some cases, no effect
is observed (Nauta et al., 2006; Sudres et al., 2006). Therefore,
the mechanisms through which MSCs suppress immune reac-
tions must be determined to offer better utility of these cells.
One prominent candidate in themechanism of MSC-mediated
immunosuppression is nitric oxide (NO) (Sato et al., 2007), a rap-
idly diffusing gaseous and bioactive molecule (Stamler et al.,
1992). NO and NO-derived reactive nitrogen species can interact
with many enzymes, ion channels, and receptors (Edwards and
Rickard, 2007; Murad, 2006). NO production is catalyzed by the
nitric oxide synthases (NOS), for which there are three genes in
humans and mice: iNOS, inducible primarily in macrophages;
nNOS, in neurons; and eNOS, in endothelial cells. iNOS expres-
sion is inducible and plays a major role in immune regulation. NO
has a well-established role in macrophage function, and recently
has been shown to affect TCR signaling, cytokine receptor
expression, and the phenotype of T cells (Niedbala et al.,
2006). At high concentrations, NO inhibits TCR-induced T cellCell Stem Cell 2, 141–150, February 2008 ª2008 Elsevier Inc. 141
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Niedbala et al., 2006). NO produced by MSCs was recently
found to suppress STAT5 phosphorylation and inhibit T cell pro-
liferation (Sato et al., 2007). The mechanism regulating iNOS ex-
pression in MSCs, however, is unknown.
One of the salient characteristics of MSCs is their ability to mi-
grate to sites of damaged tissue (Kawada et al., 2004; Wojakow-
ski and Tendera, 2005), a property that is key to their potential
use in regenerative medicine. Interestingly, MSCs have also
been shown to produce several chemokines (Chamberlain
et al., 2007; Dazzi et al., 2006; Schenk et al., 2007), which may
serve to recruit lymphocytes. Since NO is highly unstable, it
only acts locally, and it is conceivable that immune cells would
need to be recruited into close proximity with MSCs in order to
be affected by NO produced by the MSCs. According to this
premise, chemokine-mediated lymphocyte mobilization would
be a key step in MSC-mediated immunosuppression. Since
MSCs are responsive to proinflammatory cytokines, we hypoth-
esize that cytokines produced during an immune response in-
duce chemokine expression by MSCs.
In this study, we employed our cloned mouse bone marrow
MSCs to demonstrate dramatic upregulation of iNOS and che-
mokines in response to a combination of IFNg and any of the
three proinflammatory cytokines—TNFa, IL-1a, or IL-1b. We
show that chemokines promote lymphocyte migration into prox-
imity with MSCs, which produce large amounts of NO. In vivo,
MSCs attenuated delayed-type hypersensitivity (DTH) and pre-
vented the development of graft-versus-host disease (GvHD)
through a mechanism requiring IFNg and iNOS. Thus, we reveal
a fundamental mechanism through which chemokines and NO
mediate the immunosuppressive activity of MSCs.
RESULTS
The Immunosuppressive Function of MSCs
Is Induced by Proinflammatory Cytokines
The mechanism of MSC-mediated immunosuppression was ex-
amined using MSC clones generated in this laboratory. Their
‘‘stemness’’ was defined by their ability to differentiate into adi-
pocytes or osteoblast-like cells (see Figure S1 available with
this article online) and by the surface marker phenotype of
CD34CD11bCD11cCD45MHC class IICD44+Sca-1+MHC
class I low (data not shown). All results presented herein were
replicated using at least three different MSC clones.
Previous reports on immunosuppression by MSCs have had
variable results, probably due partly to different culturemethods.
Since most reports of immunosuppression by MSCs are based
on their effects on activation-induced T cell proliferation and cy-
tokine production, we first examined the direct effect ofMSCs on
T cell proliferation. CD4+ T cell blasts were generated from fresh
splenic CD4+ T cells by activation with anti-CD3 and anti-CD28
followed by expansion with IL-2 for several days (Devadas
et al., 2006; Radvanyi et al., 1996). Such T cell blasts do not pro-
duce cytokines unless restimulated through TCR. When these
T cells were cultured with MSCs, surprisingly, their IL-2-driven
proliferation was unaffected by MSCs (Figure 1A, ‘‘No sup’’).
MSCs also had no effect on CD8+ T cell blasts or T hybridoma
A1.1 cells (data not shown). Thus, in the absence of T cell cyto-
kines, MSCs do not suppress T cell proliferation.142 Cell Stem Cell 2, 141–150, February 2008 ª2008 Elsevier Inc.Most previous studies showing immunosuppression by MSCs
have examined the effects on T cells cocultured with MSCs dur-
ing T cell activation. To test whether our cloned MSCs also sup-
press T cell activation, we cocultured MSCs with fresh spleno-
cytes at graded ratios in the presence of anti-CD3 and found
that T cell proliferation was completely blocked by MSCs added
at ratios as low as 1:60 (MSC to splenocyte) (Figure 1B, ‘‘WT
MSC’’). A similar effect was found on purified CD4+ or CD8+
T cells activated by plastic-bound anti-CD3 and anti-CD28 using
MSCs between the 5th and 20th passage (data not shown). We
similarly tested the immunosuppressive capacity of many MSC
clones and found that those exhibiting better differentiation po-
tential had a greater capacity for immunosuppression (Table
S1). Thus, only when MSCs and T cells are in coculture during
T cell activation is T cell response suppressed, suggesting that
T cell cytokines may have a role.
To determine whether cytokines secreted by activated T cells
induce immunosuppression by MSCs, CD4+ T cell blasts were
cocultured with MSCs supplemented with anti-CD3-activated
whole splenocyte supernatant (SupCD3-act). The IL-2-induced
proliferation of T cells was greatly inhibited (Figure 1A, ‘‘No
Ab’’), as were CD8+ T cell blasts and A1.1 cells (data not shown).
Thus, some product(s) of activated T cells is required to induce
immunosuppression by MSCs. To identify the culpable cyto-
kines, SupCD3-act was treated with neutralizing antibodies against
various cytokines before addition to the cocultures. We found
that anti-IFNg completely restored proliferation by T cell blasts
cocultured with MSCs supplemented with SupCD3-act (Figure 1A,
‘‘anti-IFNg’’). These results implicate IFNg as a key cytokine
in this process, and reveal that under certain conditions this
major proinflammatory cytokine can instead mediate immuno-
suppression.
The effect of IFNgwas then tested directly by adding recombi-
nant IFNg to themixed cocultures ofMSC+ T cell blasts orMSC+
A1.1 cells. Surprisingly, IFNg alone did not induce immunosup-
pression (Figure 1C). Only with the concomitant addition of either
TNFa, IL-1a, or IL-1b along with IFNg did immunosuppression by
MSCs occur (Figure 1C). Therefore, while IFNg is required, it is
not sufficient; any one of the other three cytokines is also re-
quired. In fact, simultaneous neutralization of TNFa, IL-1a, and
IL-1b in SupCD3-act before addition to cocultures of MSCs and
T cell blasts completely reversed the inhibition of T cell prolifer-
ation, while the antibodies had no effect individually or in pairs
(Figure 1A and data not shown). Therefore, IFNg synergizes
with TNFa, IL-1a, or IL-1b to induce the ability of MSCs to inhibit
T cell proliferation, and TNFa, IL-1a, and IL-1b act interchange-
ably. Other proinflammatory cytokines, such as GM-CSF and
IL-6, had no effect (data not shown). While IL-1a and IL-1b are
not abundantly produced by T cells, they can be produced by
antigen-presenting cells (APCs) within the splenocyte population
in response to T cell cytokines. To determine the contribution of
APCs to the production of IL-1, we examined the effect of super-
natant from purified CD4+ or CD8+ T cells stimulated with anti-
CD3 and anti-CD28. The immunosuppressive effect was similar
to that of SupCD3-act, with supernatant from activated CD8
+
T cells being more effective than that from CD4+ T cells (data
not shown). Cytokine assay revealed that CD8+ T cells produced
more IFNg and TNFa than did CD4+ T cells, although both T cell
subpopulations produced much less IL-1a and IL-1b than did
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(A) Cloned MSCs were cultured with SupCD3-act as 50% of the
medium. Supernatant was pretreated with antibodies to neu-
tralize IFNg or TNFa, IL-1a, and IL-1b (singly or together
[3 Abs]) (20 mg/ml each). After 8 hr, fresh CD4+ T cell blasts
were added at a 1:20 ratio (MSC:T cells) along with IL-2
(200 U/ml). Cell proliferation was assessed by 3H-Tdr incorpo-
ration after 8 hr.
(B) MSCs derived from IFNgR1/ or wild-type (WT) C57BL/6
mice were cocultured with fresh C57BL/6 splenocytes plus
anti-CD3 and antibodies against IFNg, or TNFa, IL-1a, and
IL-1b (20 mg/ml each), and proliferation was assessed 48 hr
later.
(C) MSCs were supplemented with the indicated combina-
tions of recombinant cytokines (20 ng/ml each) for 8 hr, then
cocultured with CD4+ T cell blasts at a 1:20 ratio (MSC:T cells),
and proliferation was assessed after an additional 8 hr. Values
represent means ± SD of five wells from a representative of
three experiments with different clones. *p < 0.001.whole splenocytes (data not shown). As expected, anti-TNFa
partially reversed the immunosuppression induced by superna-
tant from activated purified T cells, but not that from whole sple-
nocytes (Figure 1A and data not shown). This experiment further
supports the role of APC-produced IL-1 in MSC-mediated
immunosuppression.
We found that MSCs also inhibited T cell production of IFNg,
IL-4 and TNFa (Figure S2). Because MSCs strongly inhibit IFNg
production, which at the same time is essential to induce their
immunosuppressive ability, we reasoned that MSCs must en-
counter some level of IFNg arising from initial T cell activation
before they shut down its production. Indeed, we found that
MSCs do not affect initial T cell activation, as demonstrated by
normal increases in CD69 expression in response to anti-CD3
(data not shown). As further evidence that IFNg is pivotal, we
found that MSCs derived from mice deficient in IFNg receptor 1
(IFNgR1/) were incapable of suppressing anti-CD3-induced
splenocyte proliferation in cocultures (Figure 1B). Also, none of
the five tested clones of IFNgR1/ MSCs were immunosup-
pressive (Figure S3). These results suggest that the initial pro-
duction of IFNg and other cytokines by cells in the vicinity of
MSCs is critical to induce their immunosuppressive capacity. In-
deed, anti-IFNg completely blocked the suppressive effect of
MSCs in this setting (Figure 1B), as did the 3-antibody cocktail
against TNFa, IL-1a, or IL-1b (Figure 1B), similar to their effects
when added to SupCD3-act in our testing of the effects of MSCs
on T cell blast proliferation. Therefore, the synergistic action of
IFNg and TNFa, IL-1a, or IL-1b is sufficient to induce MSCs to
become immunosuppressive.
Immunosuppression by MSCs Requires Nitric Oxide
To identify the mechanism of immunosuppression by cytokine-
exposed MSCs, we examined the proliferative response of
anti-CD3-activated splenocytes cocultured with MSCs in a
Transwell system in various configurations. When separated by
a permeable membrane, MSCs had almost no effect on T
cell proliferation (Figure S4), suggesting that a surface protein
or other locally acting factor(s) is critical. While a recent report
(Sato et al., 2007) showed that PGE-2, but not IDO, is involved,we found no effect on MSC-mediated immunosuppression
by indomethacin (a PGE-2 blocker), anti-IL-10, anti-TGFb, or
1-methyl-DL-tryptophan (1-MT, an IDO inhibitor) (Figure S5A),
ruling out these factors.
Nitric oxide at high concentrations is known to inhibit T cell re-
sponses (Niedbala et al., 2006). NO diffuses quickly from its
source (Lancaster, 1997; Vaughn et al., 1998), but the concentra-
tion of the active form drops sharply within about 100 mm. There-
fore, NO can act only in close proximity to the cells producing it.
To investigate the role of NO, its production was shut down using
a selective inhibitor of iNOS activity, NG-monomethyl-L-arginine
(L-NMMA). In mixed cocultures of MSCs and splenocytes
plus anti-CD3, normal splenocyte proliferation was restored by
L-NMMA as well as other iNOS inhibitors, such as 1400W and
L-NAME (Figure 2A and data not shown). Furthermore, iNOS-
deficient (iNOS/) MSCs failed to inhibit splenocyte prolifera-
tion, in bulk (Figure 2A) or as clones (Figure S3). In addition, we
investigated the effect of wild-type MSCs on the suppression
of the mixed lymphocyte reaction (MLR), an in vitro reflection
of GvHD. We found that MSCs also suppressed the MLR in
a manner dependent on NO and inflammatory cytokines (Fig-
ure S5B). These results strongly suggest that NO produced by
cytokine-induced MSCs mediates the suppression of T cells.
We next examined whether MSCs increase their expression of
iNOS and produce NO after exposure to proinflammatory
cytokines. MSCs were treated with SupCD3-act and the level of
iNOSmRNAwas assayed by real-time PCR. iNOSmRNAwas up-
regulated significantly in MSCs, reaching a level seven times
greater thanb-actinmRNA, indicative of extremely high expression
(Figure 2B). Concomitant addition of IFNg and TNFa to MSCs
also induced high levels of iNOS message (Figure 2C), with
IL-1a and IL-1b again being interchangeable with TNFa (data not
shown). Neutralization of cytokines in SupCD3-act showed that
anti-IFNg alone, or the 3-antibody combination against TNFa,
IL-1a and IL-1b, prevented iNOS upregulation by MSCs. When
antibodies against TNFa, IL-1a, or IL-1bwere used singly or dou-
bly, there was no effect (Figure 2C and data not shown). There-
fore, the same cytokine combinations that induce immunosup-
pression are also potent inducers of iNOS expression by MSCs.Cell Stem Cell 2, 141–150, February 2008 ª2008 Elsevier Inc. 143
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Induced MSCs Is Mediated by Nitric Oxide
(A) MSCs from iNOS/ or WT C57BL/6 mice were cocultured with
fresh C57BL/6 splenocytes plus anti-CD3, with or without the iNOS in-
hibitor, L-NMMA (1 mM). Cell proliferation was assayed after 48 hr.
(B) iNOSmRNA in MSCs cultured with SupCD3-act (50% of volume) for
various intervals was assayed by real-time PCR and compared to
b-actin mRNA, defined as 1 arbitrary unit.
(C) WT MSCs were supplemented with IFNg and TNFa (20 ng/ml
each), alone or together, or with SupCD3-act pretreated with antibodies
against the indicated cytokines, as in Figure 1A. iNOS mRNA was
assayed after 12 hr.
(D) MSCs or primary peritoneal macrophages (5 3 105/ml) were stim-
ulated with IFNg plus TNFa (20 ng/ml each) or with LPS (2 mg/ml) for
24 hr and the supernatant assayed for nitrate by a modified Griess re-
agent. mRNA data is representative of three experiments. Proliferation
and nitrate values are means ± SD of four wells from a representative
of three experiments.To determine whether iNOS expression indeed leads to NO
production, we assayed total nitrates in the supernatant of
MSCs treated with IFNg and TFNa. Nitrate production by in-
duced MSCs was at least ten times greater than that of similarly
treated CD11b+F4/80+macrophages, which are known to be co-
pious producers of NO (Figure 2D). These results are consistent
with the high levels of iNOSmRNA expression described above.
Chemoattractive Property of MSCs Is Induced
by Proinflammatory Cytokines
In several studies, effective immunosuppression byMSCs in vivo
has been achieved with as few as 1–5 cells per 1,000,000 so-
matic cells. Considering that MSCs are immobile after settling
in tissues and that secreted NO acts only very locally, cyto-
kine-induced MSCs need to attract immune cells into close
proximity to be effective. To explore this possibility, cocultures
of MSCs and splenocytes were monitored over time under the
microscope. Resting splenocytes did not move, but upon anti-
CD3-stimulation, they were observed to actively migrate toward
the spindle-shaped MSCs (Figure S6). To exclude the trivial pos-
sibility that the lack of locomotion by unstimulated splenocytes
might be due to their poor health in vitro, we examined the ability
of SupCD3-act-primed MSCs to attract A1.1 T hybridoma cells,
which survive well in the absence of IL-2. Time-lapse microvid-
eography revealed brisk migration of A1.1 cells toward MSCs
within 1.5 hr of coculture initiation (Movie S1). Therefore, MSCs
attract T cells only after exposed to proinflammatory cytokines.
To examine the role of various cytokines in enabling MSCs to
attract T cells, MSCs were pretreated with various combinations
of recombinant cytokines and the resultant migration of preacti-
vated T cells in cocultures was observed. We found that the
same T cell cytokine pairs—IFNg and TNFa, IFNg and IL-1a, or
IFNg and IL-1b—that had induced the immunosuppressive func-
tion of MSCs also caused them to attract T cells (Figure 3 and
data not shown). Likewise, using antibody neutralization of
specific cytokines, we found that migration toward MSCs was
prevented by anti-IFNg alone, or by blocking TNFa, IL-1a, and
IL-1b as a threesome (Figure S6), identical to their effects on144 Cell Stem Cell 2, 141–150, February 2008 ª2008 Elsevier Inc.SupCD3-act-induced MSC suppression of T cell proliferation and
iNOS expression.
Proinflammatory Cytokines Induce MSCs to Produce
Chemokines that Are Critical for Immunosuppression
The robust migration of activated T cells toward cytokine-primed
MSCs suggests that theMSCs secrete potent chemoattractants.
Therefore, production of leukocyte chemokines by MSCs was
tested. We found that MSCs cultured alone without cytokines
produced minimal amounts of chemokines, corroborating our
findings that unprimedMSCs cannot attract T cells. When cocul-
tured with splenocytes in the presence of anti-CD3, however,
MSCs produced several chemokines in large amounts, including
CXCL-9 (MIG) and CXCL-10 (IP-10) (Figure 4A). These are potent
T cell-specific chemokines; concentrations of less than 10 ng/ml
can drive significant chemotaxis (Loetscher et al., 1998; Meyer
Figure 3. T Cells Migrate into Proximity with MSCs Induced by
Inflammatory Cytokines
MSCs were cocultured with CD4+ T cell blasts or T hybridoma A1.1 cells (1:10
ratio) with or without IFNg and TNFa (20 ng/ml each) for 12 hr, and the extent of
cell aggregation was observed microscopically. Similar results were obtained
with several different MSC clones.
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duce Chemokines
(A) MSCs were cocultured with fresh C57BL/6 splenocytes stimulated
with anti-CD3 in the presence of the indicated antibodies (20 mg/ml
each) for 48 hr. CXCL9 and CXCL10 were tested in the supernatant
with BioPlex immunoassay.
(B) MSC clones were cultured with IFNg, TNFa, or both (20 ng/ml
each) for 12 hr, and mRNA for CXCL9 and CXCL10 were assayed as
in Figure 2.
(C) Cloned MSCs were first treated with IFNg and TNFa (20 ng/ml
each) for 8 hr, then cocultured with CD4+ T cell blasts plus IL-2 at
a 1:10 ratio in the presence of anti-CXCR3 (10 mg/ml), and proliferation
was assessed after another 8 hr. mRNA data are from a representative
of three independent experiments. For other data, values are means ±
SD of four replicate wells from a representative of three experiments.
*p < 0.001.et al., 2001). The production of chemokines was inhibited by an-
tibody neutralization of IFNg alone, or all three of TNFa, IL-1a,
and IL-1b (Figure 4A), similar to the effects on immunosuppres-
sion induction. In addition, chemokine expression was induced
by recombinant IFNg and TNFa (or IL-1a or IL-1b) (Figure 4B
and data not shown). Therefore, these cytokines are sufficient
to induce MSC-expression of chemokines, which are likely to
be responsible for driving T cell chemotaxis toward the MSCs.
To systematically examine chemokine expression by MSCs,
transcripts for 84 different chemokines and their receptors were
examined in MSCs treated with supernatant from naive or anti-
CD3-activated splenocytes (we believe that SupCD3-act is more
physiological than recombinant cytokines) using theMouseChe-
mokines andReceptorsRT2ProfilerPCRArray kit (Table 1). Strik-
ingly, treatment of MSCs with SupCD3-act resulted in a more than
1,000,000-fold increase in some chemokine gene expression,
such as CXCL2, 5, 9, and CCL7 (some even exceeding the ex-
pression level of b-actin), while naive splenocyte supernatant in-
duced insignificant chemokine mRNA, except for low levels of
CX3CL-1 (fractalkine) and CXCL13. The chemokines most highly
induced are potent in leukocyte chemotaxis. We found that anti-
body blockade of CXCR3, a receptor for the T cell chemokines
CXCL9, -10, and -11 (Lazzeri andRomagnani, 2005), significantly
reverted the suppression of T cell blast proliferation and inhibited
their chemotaxis toward MSCs (Figure 4C and data not shown),
revealing their role in immunosuppression by MSCs.
To directly test the chemotactic potential of proinflammatory
cytokine-inducedMSCs,weemployed theChemoTxChemotaxis
System. Supernatant from MSCs treated with IFNg + TNFa/IL-1
invoked brisk chemotaxis of IL-2-supplemented CD4+ and CD8+
T cell blasts in the upper chambers (Figure 5A and data not
shown). MSCs treated with SupCD3-act gave similar results
(Figure S7A). In contrast, supernatants from untreated MSCs
(Figure 5A) or activated splenocytes alonewere nonchemotactic,
aswas the direct addition of IFNg+TNFawithoutMSCs (data not
shown). Importantly, this chemotactic activity could be blocked
by antibodies against CXCR3 andCCR5, important T cell-specific
chemokine receptors (Figure 5A and Figure S7A). Cytokine-acti-
vated MSCs also attracted bone marrow-derived dendritic cells,
macrophages, and B cells (data not shown).The role of chemotaxis in the inhibition of T cell proliferation
was also examined using the ChemoTx system. MSCs were
added to the lower wells with IFNg + TNFa, and T cell blasts
(with IL-2) were added to the upper wells. Thus, chemokines pro-
duced by MSCs should induce T cell migration into the lower
wells, where NO produced by MSCs could inhibit their prolifera-
tionasdeterminedby incorporation of 3H-thymidine. Proliferation
levels of both CD4+ and CD8+ T cell blasts were found to be sig-
nificantly inhibited by MSCs in the presence of IFNg + TNFa
(Figure 5Band Figure S7B). Anti-CXCR3 and anti-CCR5 reversed
this effect. These data further support our hypothesis that T cell
chemotaxis is critical to MSC-mediated immunosuppression.
Prevention of DTH and GvHD by MSCs Is Dependent
on Inflammatory Cytokines and NO Production
Although iNOS/ MSCs are incapable of inhibiting T cell func-
tion (Figure 2A), they do produce chemokines (Figure S8), indi-
cating that chemokine production by MSCs is independent of
NO. Therefore, iNOS/ MSCs at a site of inflammation should
attract T cells and thereby promote immune reactions. To test
this prediction in the DTH response, OVA-immunized mice
were injected in the footpad with OVA alone or OVA and MSCs
from iNOS/ or wild-type mice and the resultant DTH response
measured by footpad thickness increment. As expected, admin-
istration of wild-type MSCs resulted in reduced inflammation. In
sharp contrast, iNOS/MSCsnot only did not reduce inflamma-
tion, but instead enhanced the response in comparison to
non-MSC treated mice (Figure 6A). Histological analysis showed
reduced inflammation in animals coinjected with wild-type
MSCs, but increased fluid and leukocyte infiltration with
iNOS/ MSCs (Figure 6B). Thus, NO production is required in
the suppression of an immune response in vivo. In the absence
of NO,MSC-mediated T cell recruitment enhances inflammation.
One of the striking effects of immunosuppression by MSCs is
the ability to suppress GvHD (Le Blanc et al., 2004; Le Blanc and
Ringden, 2006). To investigate whether cytokine-induced NO
production by MSC results in systemic immunosuppression
in vivo, we established the mouse GvHD model by injecting nu-
cleated bone marrow cells and splenocytes from C57BL/6 mice
into lethally irradiated F1 (C57BL/6 x C3H) mice. As expected, all
Cell Stem Cell 2, 141–150, February 2008 ª2008 Elsevier Inc. 145
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Gene Symbol Description Naive Spln Sup Activated Spln Sup Fold Increase
Cxcl9 Chemokine (C-X-C) ligand 9, MIG 4 8,963,294 2,025,082
Cxcl5 Chemokine (C-X-C) ligand 5, ENA-78 2 4,302,867 1,978,890
Cxcl2 Chemokine (C-X-C) ligand 2, Grob 2 2,711,838 1,681,250
Ccl7 Chemokine (C-C) ligand 7, MCP-3 0 24,269 1,111,786
Cxcl10 Chemokine (C-X-C) ligand 10, IP-10 111 19,719,159 177,864
Cxcl1 Chemokine (C-X-C) ligand 1, Groa 47 5,170,437 110,278
Ccl5 Chemokine (C-C) ligand 5, RANTES 215 8,022,162 37,344
Ccl2 Chemokine (C-C) ligand 2, MCP-1 3,252 11,653,869 3,584
Cxcl11 Chemokine (C-X-C) ligand 11, I-TAC 5 17,370 3,534
Ccrl2 Chemokine (C-C) receptor-like 2 110 56,765 518
Ccl17 Chemokine (C-C) ligand 17,TARC 294 23,212 79
Cx3cl1 Chemokine (C-X3-C) ligand 1, fractalkine 69,309 2,349,699 34
Cmkor1 Chemokine orphan receptor 1 32,965 617,300 19
Ccl8 Chemokine (C-C) ligand 8, MCP-2 628 10,070 16
Ccl9 Chemokine (C-C) ligand 9, MIP-1g 182 2,193 12
Ccr9 Chemokine (C-C) receptor 9 999 3,860 4
Cxcl13 Chemokine (C-X-C) ligand 13, BCA-1 19,067 48,073 3
Cxcr6 Chemokine (C-X-C) receptor 6 4,943 7,516 2
Cmklr1 Chemokine-like receptor 1 49,839 47,340 1
Ccbp2 Chemokine binding protein 2 0 9,015 N/A
Actb b-actin 10,000,000 10,000,000 1
MSCs (13 106 / T-25 flask in 5 ml) were stimulated with supernatant (Sup) from naive or activated splenocytes (Spln) as 50% of the culture medium for
12 hr. The gene expression of chemokines and chemokine receptors was assayed by real-time PCR using the Mouse Chemokines and Receptors RT2
Profiler PCR Array kit. (b-Actin defined as 1 3 107 Units.)positive-control recipient mice developed extensive GvHD be-
tween days 15 and 22, while the negative controls that received
syngeneic F1 bone marrow were unaffected. When recipient
mice were treated withMSCs after bonemarrow transplantation,
GvHD was significantly reduced: all MSC-treated mice survived
for at least 33 days, and some for more than 80 days. In contrast,
recipients treated with iNOS/ or IFNgR1/ MSCs were not
protected, as their survival was similar to untreated positive con-
trols (Figure 7A). Thus, IFNg and NO production are essential for
MSC-mediated immunosuppression in vivo.
We next examined the role of proinflammatory cytokines in
MSC-mediated protection from GvHD. F1 mice received
C57BL/6 bone marrow cells, splenocytes were injected with cy-
tokine neutralizing antibodies or L-NMMA for 7 days after wild-
type MSC infusion, and GvHD was allowed to develop. Anti-
IFNg or L-NMMA significantly reversed the protection from
GvHD conferred by wild-type MSCs (Figure 7A), while there
was no adverse response to these treatments in negative-con-
trol mice (data not shown). The effect of neutralizing TNFa, IL-1a,
and IL-1b was less dramatic, not reaching statistical signifi-
cance (Figure 7A). This result further implicates the role of IFNg
and NO production but is equivocal for the other cytokines. It
is important to recognize, however, that besides synergizing
with IFNg to induce immunosuppression by MSCs, TNFa and
IL-1 are also important factors in GvHD pathogenesis and neu-
tralization of either one has been reported to ameliorate GvHD
(Hattori et al., 1998; McCarthy et al., 1991). Therefore, it is not
surprising that protection from GvHD was not reversed to
a greater extent by these antibodies.
146 Cell Stem Cell 2, 141–150, February 2008 ª2008 Elsevier Inc.Previous studies have shown that anti-IFNg can enhance
GvHD (Yang et al., 1998). Whether the effect of IFNg is exerted
through the induction of NO production remains to be deter-
mined. Actually, in our GvHD mice not given MSCs, in compari-
son to the control group (moribund by day 15–22), GvHD severity
was slightly enhanced by treatment with anti-IFNg (day 13–18) or
L-NMMA (day 14–18), although statistically insignificant. On the
other hand, treatment with the cocktail of anti-TNFa + anti-IL1a +
anti-IL1b (day 15–29) reduced GvHD severity slightly, but was
also not statistically significant. Therefore, the dramatic effect
of MSCs on GvHD is highly likely to depend on proinflammatory
cytokine-induced production of NO.
We also performed a histological examination of the severity of
inflammation in various organs from these mice 14 days after
bone marrow transplantation. The extent of leukocyte infiltration
correlated well with the survival results: GvHD-induced mice
showed infiltration of lymphocytes in the liver, lungs, and skin,
while they were nearly absent in MSC-treated mice. In addition,
anti-IFNg and L-NMMA reversed this protection, while the 3-anti-
body cocktail against TNFa, IL-1a, and IL-1b was less effective
(Figure 7B and Figure S9). The findings of these GvHD experi-
ments, together with our DTH studies, clearly support a role for
IFNg and NO in MSC-mediated immunosuppression in vivo.
DISCUSSION
MSCs have great potential for treating various degenerative dis-
eases and immune disorders. It is safe to predict that the first
clinical application of stem cells will be the use of MSCs to
Cell Stem Cell
Immunosuppression by MSC Requires Chemokines and NOcorrect aberrant immune reactions. Previous studies by various
groups have had variable results in demonstrating immunosup-
pression by MSCs (Nauta et al., 2006; Sudres et al., 2006). Our
studies show that the immunosuppressive ability of MSCs is
not innate, but, rather, is induced by the proinflammatory cyto-
kines, IFNg in combination with TNFa, IL-1a, or IL-1b. Thus, iron-
ically, proinflammatory cytokines can lead to immunosuppres-
sion under specific circumstances. These cytokines induce
a dramatic upregulation in iNOS and several leukocyte chemo-
kines that may bring immune cells, including T cells, B cells,
and antigen-presenting cells, into close proximity with MSCs
where high levels of NO can suppress immune cell function.
Therefore, the concerted action of cytokine-induced chemo-
kines and NO are key to MSC-mediated immunosuppression
(Figure S10).
IFNg has been previously reported to be important in immuno-
suppression by human MSCs (Krampera et al., 2006; Plumas
et al., 2005). These studies concluded that IFNg-induced indole-
amine 2,3-dioxygenase (IDO) mediates immunosuppression. In
Figure 5. A Critical Role for Chemotaxis in Inflammatory Cytokine-
Induced MSC-Mediated Immunosuppression
(A) Chemotaxis assays were performed using the NeuroProbe ChemoTx Che-
motaxis Systemwith a 5-mmpore polycarbonate membrane. Culture superna-
tant from MSCs stimulated with IFNg and TNFa (20 ng/ml each) was added to
the lower chambers, and activated CD4+ or CD8+ T cell blasts plus IL-2 were
added along with anti-CXCR3 or anti-CCR5 (10 mg/ml each) to the upper
chambers. After a 3 hr incubation, the cells that migrated through the pores
and into the lower chamberswere quantitated using theMTT assay, and a che-
motaxis index was calculated.
(B) To measure their effect on T cell proliferation, MSCs were incubated in the
lower chambers with or without IFNg and TNFa (20 ng/ml each) for 24 hr. Ac-
tivated CD4+ T cell blasts were added to the upper chambers under conditions
as (A) with IL-2, incubated for 3 hr, then pulsed with 3H-thymidine for 6 hr, and
proliferation was determined. Results are representative of three experiments.contrast, we found that IFNg alone is insufficient; either TNFa
or IL-1 is also required to induce MSCs to become immunosup-
pressive. Furthermore, inhibition of IDO by 1-MT did not block
the suppressive effect (Figure S5A), corroborating a recent re-
port that also showed IDO is not involved (Sato et al., 2007).
Most significantly, our experiments reveal that the immunosup-
pressive function of MSCs is exerted through the concerted
action of chemokines and NO produced in response to proin-
flammatory cytokines.
Several factors proposed as the mechanism of immunosup-
pression by MSCs, including IL-10, TGF-b, PGE2, as well as
IDO, were ruled out by our blocking studies. In addition, we
found that immunosuppression by MSCs does not affect T cell
expression of CD69 or CD25 (Xu et al., 2007a), while TGF-b,
IL-10, and PGE2 do. We show instead that T cell cytokine-
induced immunosuppression by MSCs can be completely
blocked by inhibiting iNOSwith L-NMMA, in agreement with a re-
cent report (Sato et al., 2007). In fact, iNOS was highly upregu-
lated in MSCs by proinflammatory cytokines. Our most definitive
proof of the central role of NO is that iNOS-deficient MSCs lack
immunosuppressive capability.
Various studies have shown thatMSCs expanded ex vivo pref-
erentially home to sites of tissue damage, where they enhance
wound healing, support tissue regeneration, restore the bone
marrow microenvironment following damage by myeloablative
chemotherapy, or integrate into tumors (Ries et al., 2007). This
specific migration of MSCs is reportedly guided by chemokines;
in fact, recent studies found that MSCs express the chemokine
receptors CCR1, CCR4, CCR7, CXCR5, and CCR10 (Von Lutti-
chau et al., 2005). MSCs also produce chemokines, as previ-
ously shown (Honczarenko et al., 2006). Our real-time PCR anal-
ysis found that cytokine-induced MSCs express very high levels
of several leukocyte chemokines, most notably CXCL9,
CXCL10, and CXCL11 (Table 1), which are ligands for the
T cell-specific chemokine receptor, CXCR3. Neutralization of
CXCR3 reversed immunosuppression by MSCs, demonstrating
the critical role of leukocyte recruitment by MSCs. Considering
the limited diffusion and short half-life of NO, these mechanisms
may serve to attract and retain lymphocytes in close proximity
with MSCs where the locally high concentrations of NO could
suppress T cell function.
A question that arises is what happens to T cells in proximity
with inflammatory cytokine-stimulated MSCs?We have recently
reported that in the absence of T cell activation or exogenous in-
flammatory cytokines,MSCs actually prolong the survival of lym-
phocytes (Xu et al., 2007b). In contrast, with T cell activation orFigure 6. iNOS-Deficient MSCs Boost DTH
(A) C57BL/6 mice were immunized with OVA in complete Freund’s ad-
juvant by tail base injection. Mice were challenged in the footpad with
200 mg aggregated OVA administered with or without wild-type or
iNOS/ MSCs (2.5 3 105 cells) on day 7. Footpad thickness incre-
ment was determined after 24 hr as a measure of DTH. Data shown
are means ± SD of a representative of three experiments. *p < 0.005
versus OVA alone.
(B) Footpad tissue was fixed for H&E-stained histological sections.
Representative of three experiments.
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cells first enter cell-cycle arrest and then die within 24 hr
(Figure S11). We also found this apoptosis to depend on NO,
since T cell apoptosis was not observed when iNOS inhibitors
were used. Apoptosis was also absent when iNOS/ or
IFNgR1/MSCswere used (data not shown). Therefore, NO-in-
duced cell-cycle arrest and apoptosis of activated T cells are
part of the mechanism of immunosuppression mediated by in-
flammatory cytokine-activated MSCs.
Our studies demonstrate that immunosuppression byMSCs is
exerted through the coordinated action of cytokine-induced
chemokines and NO. In vitro, chemical blockade of iNOS re-
verted immunosuppression. In addition, injection of iNOS/
MSCs actually enhanced the DTH response, confirming the
role of iNOS in vivo, and supporting our hypothesis thatMSCs re-
cruit lymphocytes. These results suggest the following scenario:
chemokines produced by MSCs attract lymphocyte to the site of
antigenic challenge, where their activity is inhibited by MSC-
produced NO. Without NO, lymphocytes remain fully functional,
increasing the immune reactivity. Based on this premise, we hy-
pothesize that in the presence of an active immune reaction, ad-
ministered MSCs localize to the inflammatory site, immediately
acquire their immunosuppressive function, and thus become ef-
fective in attenuating the ongoing immune response. On the
other hand, in the absence of tissue damage and active inflam-
mation, administered MSCs would neither localize specifically
nor become immunosuppressive.
Figure 7. MSCs Prevented GvHD in a Manner Dependent on Inflam-
matory Cytokines and NO
(A) Recipient mice (C57BL/6 x C3H, F1) were lethally irradiated and injected i.v.
with C57BL/6 bone marrow cells plus splenocytes. On days 3 and 7 after bone
marrow transplantation, recipients were administered with the indicated
MSCs. For some WT MSC groups, L-NMMA, anti-IFNg or a 3-antibody cock-
tail against TNFa, IL-1a, and IL-1b (3 Abs) were injected i.p. Survival was mon-
itored daily for 12 weeks.
(B) H&E-stained sections of liver from different groups at day 14 were exam-
ined histologically. Representative micrographs are shown.148 Cell Stem Cell 2, 141–150, February 2008 ª2008 Elsevier Inc.In organ transplant and bone marrow transplant, T cells of
donor origin can recognize the recipient’s MHC and lead to the
development of GvHD. This often fatal disease is frequently un-
responsive to various immunosuppressive therapies (Lu et al.,
1996; Shlomchik, 2007), but new approaches targeting immune
modulatory molecules show great promise in treating GvHD (Ja-
cobsohn, 2002; Tamada et al., 2000; Xu et al., 2007c). Most re-
cently, MSCs have been shown to be highly effective in the treat-
ment of GvHD in preclinical and clinical trials (Aggarwal and
Pittenger, 2005; Inoue et al., 2006; Keating, 2006; Le Blanc
et al., 2004; Nauta et al., 2006; Rasmusson et al., 2005; Sudres
et al., 2006). Still, the mechanisms underlying MSC-mediated
suppression of GvHD remain elusive. Our studies demonstrate
that MSCs suppress GvHD through the production of NO after
stimulation with proinflammatory cytokines. Additional studies
should lead to a more complete understanding of this phenom-
enon and allow its better clinical utilization.
EXPERIMENTAL PROCEDURES
Mice
Male C57BL/6, C3H/HeJCr, and F1 (C57BL/6 x C3H) mice, 6–8 weeks old,
were from the National Cancer Institute (Frederick, MD). IFNg-R1/ mice
(Ifngr1tm1Agt) and iNOS/ mice (Nos2tm1Lau) were from Jackson Laboratory
(Bar Harbor, ME). Mice were maintained in the Robert Wood Johnson Medical
School Vivarium. Animals were matched for age and gender in each experi-
ment, all approved by the Institutional Animal Care and Use Committee.
Reagents
Recombinant mouse IFNg, TNFa, IL-1a, and IL-1b; monoclonal antibodies
against mouse TNFa, IL-1a, IL-1b, and CCR5; FITC-conjugated anti-mouse
CD11b, and PE-conjugated anti-mouse F4/80 were from eBiosciences (La
Jolla, CA). Recombinant mouse M-CSF and antibodies against IL-10 and
TGF-bwere from R&D Systems (Minneapolis, MN). Anti-IFNgwas from Harlan
(Indianapolis, IN). Anti-CXCR3 was from Invitrogen (Carlsbad, CA). Indometh-
acin, 1-methyl-DL-tryptophan (1-MT), and NG-monomethyl-L-arginine
(L-NMMA) were from Sigma-Aldrich (St. Louis, MO).
Cells
MSCs were generated from bone marrow of tibia and femur of 6- to 10-week-
old mice. Cells were cultured in a-MEMmedium supplemented with 10%FBS,
2 mM glutamine, 100 U/ml penicillin, and 100 mg/ml streptomycin (all from In-
vitrogen). Nonadherent cells were removed after 24 hr, and adherent cells were
maintained with medium replenishment every 3 days. To obtain MSC clones,
cells at confluence were harvested and seeded into 96-well plates by limited
dilution. Individual clones were then picked and expanded. Cells were used
at 5th to 20th passage.
T cell blasts were generated from CD4+ T cells purified by negative selection
with CD4+ T cell subset isolation kits (R&D Systems). Cells (1 3 106 cells /ml)
were activated by plastic-bound anti-CD3 and soluble anti-CD28 for 48 hr,
then cultured with IL-2 (200 U/ml) alone for 48 hr. All T cell cultures were main-
tained in RPMI-1640 medium supplemented with 10% heat-inactivated FBS,
2 mM glutamine, 100 U/ml penicillin, 100 mg/ml streptomycin, and 50 mM
b-ME (complete medium).
Activated splenocyte supernatant was harvested from 48 hr cultures of sple-
nocytes (23 106/ml) activated by plastic-bound anti-CD3, then 0.1 mm filtered
and frozen.
Detection of Cytokines, Chemokines, and NO
Culture supernatants were assayed for 20 different cytokines and chemokines
with a multiplex bead array kit (Invitrogen, Carlsbad, CA) using Luminex Tech-
nology (Bio-Plex System, Bio-Rad, Hercules, CA). IFNgwas assayed by ELISA
(BD Biosciences, San Jose, CA). NO was detected using a modified Griess re-
agent (Sigma-Aldrich). Briefly, all NO3 is converted into NO2 by nitrate reduc-
tase, and total NO2 detected by the Griess reaction (Miranda et al., 2001).
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RNAwas isolated from cell pellets using an RNeasyMini Kit. First-strand cDNA
synthesis was performed using Sensiscript RT Kit with random hexamer
primers (all kits from QIAGEN, Valencia, CA). mRNA of the genes of interest
were quantitated by real-time PCR (MX-4000 from Stratagene, La Jolla, CA)
using SYBR Green Master Mix (Applied Biosystems, Foster City, CA). Total
amount of mRNA was normalized to endogenous b-actin mRNA. Primers se-
quences for iNOS were: forward, 50-CAGCTGGGCTGTACAAACCTT-30; re-
verse, 50-CATTGGAAGTGAAGCGTTTCG-30. Other primers were from the
RT2 Profiler PCR Array Mouse Chemokines & Receptors kit (Superarray, Fred-
erick, MD).
Chemotaxis Assay
Chemotaxis was tested with the NeuroProbe ChemoTx Chemotaxis System
(NeuroProbe, Gaithersburg, MD), as described (Shi et al., 1993). The lower
chambers of the 96-well plate were filled with supernatant from MSCs stimu-
lated with IFNg plus TNFa (20 ng/ml each) or SupCD3-act (1:2 dilution). A poly-
vinylpyrrolidine-free polycarbonate membrane with 5 mmpores was then over-
laid. T cell blasts (1.25 3 105) were added to the top chambers. After a 3 hr
incubation, cells that had migrated through pores and into bottom wells
were quantitated using MTT assay (Shi et al., 1993). A chemotaxis index
was calculated as the ratio of the number of T cell blasts migrated in response
to MSCs compared to the number migrating to medium alone.
The immunosuppression resulting from T cell migration toward inflammatory
cytokine-activated MSCs was examined in a similar set up. MSCs (2 3 104)
were added to the lower chamber with or without stimulation with IFNg and
TNFa (20 ng/ml each) for 24 hr. Activated T cell blasts were then added to
the upper chamber as above. IL-2 was added to both chambers. After 3 hr,
both chambers were pulsed with 3H-thymidine, and cell proliferation assessed
6 hr later.
GvHD Induction and Modulation by MSCs
C57BL/6 x C3H F1 mice at 8-weeks old were lethally irradiated (13 Gy) and af-
ter 24 hr were infused by tail vein injection with nucleated bone marrow cells
(5 3 106) and splenocytes (5 3 106) isolated from C57BL/6 parent mice. On
days 3 and 7 following bone marrow transplantation, the recipients were ad-
ministrated with 0.53 106 MSCs derived from C57BL/6 wild-type, IFNgR1/,
or iNOS/ mice via the tail vein. Some wild-type MSC groups were also
injected i.p. with the iNOS inhibitor, NG-monomethyl L-arginine (L-NMMA,
500 mg/mouse), anti-IFNg (400 mg/mouse), or a cocktail of three antibodies
against TNFa, IL-1a, and IL-1b (200 mg each/mouse) daily for 7 days starting
immediately after the first MSC administration. As negative controls, the F1
mice were injected with F1 bone marrow cells. Mice were observed daily for
GvHD signs (wasting, ruffled hair, and hunched back) and euthanized upon
becoming moribund, thus marking survival time. On day 14, various tissues
were collected, and 5 mm paraffin sections were prepared and stained with
hematoxylin/eosin (H&E).
Induction of DTH Response and Histology Analysis
C57BL/6 mice (6- to 8-weeks-old) were immunized by tail base injection of ov-
albumin (OVA, 10 mg in 50 ml saline) emulsified with 50 ml complete Freund’s
adjuvant. DTH was tested after 5 days, by challenging with 200 mg aggregated
OVA in 30 ml saline injected into the right hind footpad. The left footpad was in-
jected with 30 ml of saline as a negative control. After 24 hr, antigen-induced
footpad thickness increment was measured using a caliper and calculated
as: (Rimm  Limm)  (Runimm  Lunimm), where R and L are thickness of right
and left footpads.
Statistical Analysis
Significance was assessed by unpaired two-tailed Student’s t test or analysis
of variance (ANOVA).
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